REC-7735 / Recursion Pharma - LARVOL DELTA

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) - "Upcoming milestones: REC-617 (CDK7): On track to initiate CDK7 combination studies in 1H25, additional monotherapy data expected in 2H25; REC-7735 (PI3Kα H1047R): Preclinical studies ongoing with development candidate expected in 2H25; REC-1245 (RBM39): Early Phase 1 safety and PK monotherapy data expected in 1H26."

P1 data • P1/2 data • Pipeline update • Solid Tumor